Takeaways: Alberta’s coverage broadens Elidel’s public-access footprint in Canada and should make it easier for dermatologists to use a non-corticosteroid topical when conventional therapies are...
Takeaways: Quebec’s listing of PrOKEDI on the RAMQ formulary is a key commercial milestone for Bausch Health, turning a specialized, once‑monthly long‑acting risperidone into a publicl...
Takeaways: The pCPA Letter of Intent for PrOKEDI (risperidone LAI) moves Bausch Health toward public reimbursement and broader access for Canada’s schizophrenia population, w...
